Launois, R[Author] - Search Results

Year	Number of Results
1989	3
1990	1
1992	2
1994	3
1996	3
1997	3
1998	1
2000	1
2001	4
2002	2
2003	2
2004	2
2005	1
2006	4
2007	2
2008	4
2010	2
2011	4
2012	2
2013	2
2014	4
2015	2
2016	3
2018	1
2019	1
2020	3
2021	3
2022	2
2024	1
2025	1
2026	1

1

Is a Hybrid Pulmonary Rehabilitation Programme Feasible and Effective in Individuals With COPD After an Exacerbation-Related Hospitalisation: A Mixed Methods Study.

Gephine S, Meto E, Le Rouzic O, Launois R, Grosbois JM. Gephine S, et al. Among authors: launois r. J Clin Nurs. 2026 Feb 4. doi: 10.1111/jocn.70234. Online ahead of print. J Clin Nurs. 2026. PMID: 41636329

2

Cost comparison of four venous catheters: Short peripheral catheter, Long peripheral line, Midline, and PICC for peripheral infusion.

Meto E, Cabout E, Rosay H, Espinasse F, Lot AS, Hajjam ME, Gnamien Clermont S, Launois R. Meto E, et al. Among authors: launois r. J Vasc Access. 2025 May;26(3):966-974. doi: 10.1177/11297298241258257. Epub 2024 Jun 10. J Vasc Access. 2025. PMID: 38855974

3

Barriers and Expectations for Patients in Post-Osteoporotic Fracture Care in France: The EFFEL Study.

Launois R, Cabout E, Benamouzig D, Velpry L, Briot K, Alliot F, Perrin L, Grange L, Sellami R, Touboul C, Joubert JM, Roux C. Launois R, et al. Value Health. 2022 Apr;25(4):571-581. doi: 10.1016/j.jval.2021.10.005. Epub 2021 Nov 25. Value Health. 2022. PMID: 35365301 Free article.

4

[Realist protocol for implementing integrated care pathways in France (waiver 51 LFSS 2018)].

Launois R, Diard M, Cabout E, Meto E, Eymere S. Launois R, et al. Ann Pharm Fr. 2022 Mar;80(2):131-144. doi: 10.1016/j.pharma.2021.06.004. Epub 2021 Jun 18. Ann Pharm Fr. 2022. PMID: 34153238 Review. French.

5

Cost-effectiveness of Emollients in the Prevention of Relapse among French Patients with Atopic Dermatitis.

Cabout E, Eymere S, Launois R, Séité S, Delvigne V, Taïeb C, Reguai Z. Cabout E, et al. Among authors: launois r. Acta Derm Venereol. 2021 Jul 30;101(7):adv00509. doi: 10.2340/00015555-3873. Acta Derm Venereol. 2021. PMID: 34230978 Free PMC article.

6

Cost Effectiveness of Emollients in the Prevention of Relapses in Atopic Dermatitis.

Cabout E, Eymere S, Launois R, Aslanian F, Taïeb C, Seité S. Cabout E, et al. Among authors: launois r. Clin Cosmet Investig Dermatol. 2020 Dec 21;13:987-996. doi: 10.2147/CCID.S279233. eCollection 2020. Clin Cosmet Investig Dermatol. 2020. PMID: 33376376 Free PMC article.

7

Real-world care for individuals aged over fifty with fractures in France: Evidence for a wide care gap-The EPIFRACT Study.

Briot K, Grange L, Cortet B, Feron JM, Chauvin P, Coulomb A, Alliot-Launois F, Sellami R, Touboul C, Perrin L, Joubert JM, Launois R. Briot K, et al. Among authors: launois r. Joint Bone Spine. 2020 Oct;87(5):467-473. doi: 10.1016/j.jbspin.2020.04.007. Epub 2020 May 5. Joint Bone Spine. 2020. PMID: 32387150

8

Fragility fractures in France: epidemiology, characteristics and quality of life (the EPIFRACT study).

Cortet B, Chauvin P, Feron JM, Grange L, Coulomb A, Launois R, Alliot-Launois F, Sellami R, Touboul C, Vincent B, Joubert JM, Briot K. Cortet B, et al. Among authors: launois r. Arch Osteoporos. 2020 Mar 13;15(1):46. doi: 10.1007/s11657-019-0674-2. Arch Osteoporos. 2020. PMID: 32170512

9

Importance of out-of-pocket costs for adult patients with atopic dermatitis in France.

Launois R, Ezzedine K, Cabout E, Reguai Z, Merrhand S, Heas S, Seneschal J, Misery L, Taieb C. Launois R, et al. J Eur Acad Dermatol Venereol. 2019 Oct;33(10):1921-1927. doi: 10.1111/jdv.15581. Epub 2019 Apr 10. J Eur Acad Dermatol Venereol. 2019. PMID: 30887577

10

[How to measure real-world effectiveness?].

Launois R, Trouiller JB, Cabout E. Launois R, et al. Ann Pharm Fr. 2018 Nov;76(6):421-435. doi: 10.1016/j.pharma.2018.07.003. Epub 2018 Aug 10. Ann Pharm Fr. 2018. PMID: 30103940 Review. French.

11

Venous symptoms: the SYM Vein Consensus statement developed under the auspices of the European Venous Forum.

Perrin M, Eklof B, VAN Rij A, Labropoulos N, Vasquez M, Nicolaides A, Blattler W, Bouhassira D, Bouskela E, Carpentier P, Darvall K, DE Maeseneer M, Flour M, Guex JJ, Hamel-Desnos C, Kakkos S, Launois R, Lugli M, Maleti O, Mansilha A, NEGLéN P, Rabe E, Shaydakov E. Perrin M, et al. Among authors: launois r. Int Angiol. 2016 Aug;35(4):374-98. Epub 2016 Apr 15. Int Angiol. 2016. PMID: 27081866 No abstract available.

12

Cost-effectiveness analysis of rifaximin-α administration for the reduction of episodes of overt hepatic encephalopathy in recurrence compared with standard treatment in France.

Kabeshova A, Ben Hariz S, Tsakeu E, Benamouzig R, Launois R. Kabeshova A, et al. Among authors: launois r. Therap Adv Gastroenterol. 2016 Jul;9(4):473-82. doi: 10.1177/1756283X16644249. Epub 2016 May 1. Therap Adv Gastroenterol. 2016. PMID: 27366216 Free PMC article.

13

Psychometric Validation of the 14 items ChronIc Venous Insufficiency Quality of Life Questionnaire (CIVIQ-14): Confirmatory Factor Analysis.

Le Moine JG, Fiestas-Navarrete L, Katumba K, Launois R. Le Moine JG, et al. Among authors: launois r. Eur J Vasc Endovasc Surg. 2016 Feb;51(2):268-74. doi: 10.1016/j.ejvs.2015.08.020. Epub 2015 Oct 28. Eur J Vasc Endovasc Surg. 2016. PMID: 26520178 Free article.

14

Health-related quality-of-life scales specific for chronic venous disorders of the lower limbs.

Launois R. Launois R. J Vasc Surg Venous Lymphat Disord. 2015 Apr;3(2):219-27.e1-3. doi: 10.1016/j.jvsv.2014.08.005. Epub 2014 Oct 29. J Vasc Surg Venous Lymphat Disord. 2015. PMID: 26993844 Free article.

15

Systematic review and bivariate/HSROC random-effect meta-analysis of immunochemical and guaiac-based fecal occult blood tests for colorectal cancer screening.

Launois R, Le Moine JG, Uzzan B, Fiestas Navarrete LI, Benamouzig R. Launois R, et al. Eur J Gastroenterol Hepatol. 2014 Sep;26(9):978-89. doi: 10.1097/MEG.0000000000000160. Eur J Gastroenterol Hepatol. 2014. PMID: 25072382

16

Linguistic validation of the 20 item-chronic venous disease quality-of-life questionnaire (CIVIQ-20).

Launois R, Mansilha A, Lozano F. Launois R, et al. Phlebology. 2014 Aug;29(7):484-7. doi: 10.1177/0268355513479582. Epub 2013 May 3. Phlebology. 2014. PMID: 23563648

17

Health economic value of an innovation: delimiting the scope and framework of future market entry agreements.

Launois R, Navarrete LF, Ethgen O, Le Moine JG, Gatsinga R. Launois R, et al. J Mark Access Health Policy. 2014 Jun 23;2. doi: 10.3402/jmahp.v2.24988. eCollection 2014. J Mark Access Health Policy. 2014. PMID: 27226844 Free PMC article.

18

[Risk-sharing agreements: choice of study design and assessment criteria].

Launois R, Ethgen O. Launois R, et al. Ann Pharm Fr. 2013 Sep;71(5):346-57. doi: 10.1016/j.pharma.2013.08.009. Epub 2013 Sep 4. Ann Pharm Fr. 2013. PMID: 24075705 French.

19

Primary prevention of colorectal cancer with low-dose aspirin in combination with endoscopy: a cost-effectiveness analysis.

Hassan C, Rex DK, Cooper GS, Zullo A, Launois R, Benamouzig R. Hassan C, et al. Among authors: launois r. Gut. 2012 Aug;61(8):1172-9. doi: 10.1136/gutjnl-2011-300206. Epub 2011 Oct 13. Gut. 2012. PMID: 21997545 Clinical Trial.

20

Construction and international validation of CIVIQ-14 (a short form of CIVIQ-20), a new questionnaire with a stable factorial structure.

Launois R, Le Moine JG, Lozano FS, Mansilha A. Launois R, et al. Qual Life Res. 2012 Aug;21(6):1051-8. doi: 10.1007/s11136-011-0008-3. Epub 2011 Sep 25. Qual Life Res. 2012. PMID: 21947689

21

Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis.

Launois R, Avouac B, Berenbaum F, Blin O, Bru I, Fautrel B, Joubert JM, Sibilia J, Combe B. Launois R, et al. J Rheumatol. 2011 May;38(5):835-45. doi: 10.3899/jrheum.100665. Epub 2011 Jan 15. J Rheumatol. 2011. PMID: 21239748 Free article.

22

Costs of managing severe immune thrombocytopenia in adults: a retrospective analysis.

Khellaf M, Le Moine JG, Poitrinal P, Francesconi C, Haddad A, Bierling P, Michel M, Eckert L, Launois R, Godeau B. Khellaf M, et al. Among authors: launois r. Ann Hematol. 2011 Apr;90(4):441-6. doi: 10.1007/s00277-010-1087-x. Epub 2010 Oct 5. Ann Hematol. 2011. PMID: 20922528

23

International psychometric validation of the Chronic Venous Disease quality of life Questionnaire (CIVIQ-20).

Launois R, Mansilha A, Jantet G. Launois R, et al. Eur J Vasc Endovasc Surg. 2010 Dec;40(6):783-9. doi: 10.1016/j.ejvs.2010.03.034. Epub 2010 Oct 29. Eur J Vasc Endovasc Surg. 2010. PMID: 20920862 Free article.

24

Budget impact model of rituximab after failure of one or more TNFalpha inhibitor therapies in the treatment of rheumatoid arthritis.

Launois R, Payet S, Saidenberg-Kermanac'h N, Francesconi C, França LR, Boissier MC. Launois R, et al. Joint Bone Spine. 2008 Dec;75(6):688-95. doi: 10.1016/j.jbspin.2008.04.012. Epub 2008 Oct 31. Joint Bone Spine. 2008. PMID: 18951825

25

Drotrecogin alfa's impact on intensive care workload in real life practice: a propensity score approach.

Riou França L, Payet S, Le Lay K, Launois R. Riou França L, et al. Among authors: launois r. Value Health. 2008 Dec;11(7):1051-60. doi: 10.1111/j.1524-4733.2008.00319.x. Epub 2008 May 20. Value Health. 2008. PMID: 18494757 Free article.

26

An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom.

Brown B, Diamantopoulos A, Bernier J, Schöffski P, Hieke K, Mantovani L, Launois R, Griebsch I, Robinson P. Brown B, et al. Among authors: launois r. Value Health. 2008 Sep-Oct;11(5):791-9. doi: 10.1111/j.1524-4733.2007.00302.x. Epub 2008 Jan 11. Value Health. 2008. PMID: 18194407 Free article. Clinical Trial.

27

Assessment of the cost effectiveness of travoprost versus latanoprost as single agents for treatment of glaucoma in France.

Payet S, Denis P, Berdeaux G, Launois R. Payet S, et al. Among authors: launois r. Clin Drug Investig. 2008;28(3):183-98. doi: 10.2165/00044011-200828030-00005. Clin Drug Investig. 2008. PMID: 18266403

28

Comparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UK NHS system.

Le Lay K, Myon E, Hill S, Riou-Franca L, Scott D, Sidhu M, Dunlop D, Launois R. Le Lay K, et al. Among authors: launois r. Eur J Health Econ. 2007 Jun;8(2):145-51. doi: 10.1007/s10198-006-0034-1. Epub 2007 Feb 28. Eur J Health Econ. 2007. PMID: 17333088

29

Cost-effectiveness of activated protein C in real-life clinical practice.

Dhainaut JF, Payet S, Vallet B, França LR, Annane D, Bollaert PE, Le Tulzo Y, Runge I, Malledant Y, Guidet B, Le Lay K, Launois R; PREMISS Study Group. Dhainaut JF, et al. Among authors: launois r. Crit Care. 2007;11(5):R99. doi: 10.1186/cc6116. Crit Care. 2007. PMID: 17822547 Free PMC article.

30

[Evidence data and importance of public health of the new antipsychotics].

Launois R. Launois R. Encephale. 2006 Oct;32(5 Pt 3):S861-5. doi: 10.1016/s0013-7006(06)76247-9. Encephale. 2006. PMID: 17119488 French. No abstract available.

31

[Economic aspects of telemedicine].

Launois R. Launois R. Bull Acad Natl Med. 2006 Feb;190(2):367-77; discussion 377-9. Bull Acad Natl Med. 2006. PMID: 17001867 French.

32

Comparison of diurnal intraocular pressure control by latanoprost versus travoprost : results of an observational survey.

Denis P, Launois R, Devaux M, Berdeaux G. Denis P, et al. Among authors: launois r. Clin Drug Investig. 2006;26(12):703-14. doi: 10.2165/00044011-200626120-00004. Clin Drug Investig. 2006. PMID: 17274677

33

Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure.

Riou França L, Launois R, Le Lay K, Aegerter P, Bouhassira M, Meshaka P, Guidet B. Riou França L, et al. Among authors: launois r. Int J Technol Assess Health Care. 2006 Winter;22(1):101-8. doi: 10.1017/s0266462306050896. Int J Technol Assess Health Care. 2006. PMID: 16673686

34

[Cost analysis of the strategies in the treatment of schizophrenics: the place of sustained release injectable atypical antipsychotics].

Gasquet I, Bouhassira M, Launois R. Gasquet I, et al. Among authors: launois r. Encephale. 2005 Jul-Aug;31(4 Pt 1):517-8. Encephale. 2005. PMID: 16389719 French. No abstract available.

35

Translation and validation of a quality of life questionnaire for chronic lower limb venous insufficiency into greek.

Erevnidou K, Launois R, Katsamouris A, Lionis C. Erevnidou K, et al. Among authors: launois r. Int Angiol. 2004 Dec;23(4):394-9. Int Angiol. 2004. PMID: 15767986

36

Estimating the cost-effectiveness of stroke units in France compared with conventional care.

Launois R, Giroud M, Mégnigbêto AC, Le Lay K, Présenté G, Mahagne MH, Durand I, Gaudin AF. Launois R, et al. Stroke. 2004 Mar;35(3):770-5. doi: 10.1161/01.STR.0000117574.19517.80. Epub 2004 Feb 19. Stroke. 2004. PMID: 14976321

37

[Costs, costs and more costs: which one should we use?].

Launois R, Vergnenègre A, Garrigues B. Launois R, et al. Bull Cancer. 2003 Nov;90(11):946-54. Bull Cancer. 2003. PMID: 14706897 Free article. French.

38

[Economic assessment, a field between clinical research and observational studies].

Launois R. Launois R. Bull Cancer. 2003 Jan;90(1):97-104. Bull Cancer. 2003. PMID: 12609811 Free article. French.

39

Quality of life (Spain and France): validation of the chronic venous insufficiency questionnaire (CIVIQ).

Lozano FS, Launois R; Reflux Assessment and Quality of Life Improvement with Micronized Flavonoids (RELIEF) Spanish group. Lozano FS, et al. Among authors: launois r. Methods Find Exp Clin Pharmacol. 2002 Sep;24(7):425-9. doi: 10.1358/mf.2002.24.7.696544. Methods Find Exp Clin Pharmacol. 2002. PMID: 12428431 Free article.

40

[Lymphedema and quality of life].

Alliot F, Launois R. Alliot F, et al. Among authors: launois r. Rev Med Interne. 2002 Jun;23 Suppl 3:431s-435s. doi: 10.1016/s0248-8663(02)80388-5. Rev Med Interne. 2002. PMID: 12162209 Review. French.

41

Internet pharmaco-economic studies in metastatic colorectal cancer.

Launois R, Portafax C, Le Lay K, Mègnigbêto A, Perrocheau G. Launois R, et al. Crit Rev Oncol Hematol. 2001 Apr;38(1):63-77. doi: 10.1016/s1040-8428(00)00125-6. Crit Rev Oncol Hematol. 2001. PMID: 11255082 Review.

42

[Quality is expensive].

Launois R. Launois R. Therapie. 2001 Mar-Apr;56(2):93-8. Therapie. 2001. PMID: 11471380 French.

43

[The European Evaluation of Vertigo (EEV) scale: a clinical validation study].

Mègnigbêto CA, Sauvage JP, Launois R. Mègnigbêto CA, et al. Among authors: launois r. Rev Laryngol Otol Rhinol (Bord). 2001;122(2):95-102. Rev Laryngol Otol Rhinol (Bord). 2001. PMID: 11715268 French.

44

A cost-effectiveness analysis of stays in intensive care units.

Sznajder M, Aegerter P, Launois R, Merliere Y, Guidet B, CubRea. Sznajder M, et al. Among authors: launois r. Intensive Care Med. 2001 Jan;27(1):146-53. doi: 10.1007/s001340000760. Intensive Care Med. 2001. PMID: 11280626

45

[Evaluation of the quality of life of schizophrenic patients: validation of the brief version of the Quality of Life Interview].

Lancon C, Auquier P, Launois R, Toumi M, Llorca PM, Bebbington P, Lehman A. Lancon C, et al. Among authors: launois r. Encephale. 2000 Jul-Aug;26(4):11-6. Encephale. 2000. PMID: 11064834 French.

46

[Cost of illness: an inextricable maze or an aid in decision making? The case of schizophrenia].

Launois R, Toumi M, Reboul-Marty J, Lançon C. Launois R, et al. Encephale. 1998 Mar-Apr;24(2):83-99. Encephale. 1998. PMID: 9622787 Review. French.

47

[Quality of life].

Launois R. Launois R. Rech Soins Infirm. 1997 Sep;(50):116-8. Rech Soins Infirm. 1997. PMID: 9370748 French. No abstract available.

48

[A medico-economic evaluation of second line chemotherapy in metastatic breast cancer: comparison between docetaxel, paclitaxel, and vinorelbine].

Launois RJ, Reboul-Marty JM, Bonneterre J. Launois RJ, et al. Bull Cancer. 1997 Jul;84(7):709-21. Bull Cancer. 1997. PMID: 9339197 Review. French.

49

Evaluation of ibuprofen versus aspirin and paracetamol on efficacy and comfort in children with fever.

Autret E, Reboul-Marty J, Henry-Launois B, Laborde C, Courcier S, Goehrs JM, Languillat G, Launois R. Autret E, et al. Among authors: launois r. Eur J Clin Pharmacol. 1997;51(5):367-71. doi: 10.1007/s002280050215. Eur J Clin Pharmacol. 1997. PMID: 9049576 Clinical Trial.

50

Construction and validation of a quality of life questionnaire in chronic lower limb venous insufficiency (CIVIQ).

Launois R, Reboul-Marty J, Henry B. Launois R, et al. Qual Life Res. 1996 Dec;5(6):539-54. doi: 10.1007/BF00439228. Qual Life Res. 1996. PMID: 8993100 Clinical Trial.

51

A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine.

Launois R, Reboul-Marty J, Henry B, Bonneterre J. Launois R, et al. Pharmacoeconomics. 1996 Nov;10(5):504-21. doi: 10.2165/00019053-199610050-00008. Pharmacoeconomics. 1996. PMID: 10169397

52

Pooling public and private funds in the patient's interest: the case for long-term care insurance.

Launois R. Launois R. Soc Sci Med. 1996 Sep;43(5):739-44. doi: 10.1016/0277-9536(96)00118-9. Soc Sci Med. 1996. PMID: 8870138

53

Chemonucleolysis versus surgical discectomy for sciatica secondary to lumbar disc herniation. A cost and quality-of-life evaluation.

Launois R, Henry B, Marty JR, Gersberg M, Lassale C, Benoist M, Goehrs JM. Launois R, et al. Pharmacoeconomics. 1994 Nov;6(5):453-63. doi: 10.2165/00019053-199406050-00007. Pharmacoeconomics. 1994. PMID: 10155273

54

At the crossroads of venous insufficiency and hemorrhoidal disease: Daflon 500 mg--repercussions of venous insufficiency on everyday life.

Launois R. Launois R. Angiology. 1994 Jun;45(6 Pt 2):495-504. Angiology. 1994. PMID: 8203779

55

[Integration of patients' preferences in individual and collective health choices].

Launois R. Launois R. Rev Epidemiol Sante Publique. 1994;42(3):246-62. Rev Epidemiol Sante Publique. 1994. PMID: 8209082 Review. French.

56

Cost-effectiveness analysis of strategies for screening prostatic cancer.

Launois R. Launois R. Dev Health Econ Public Policy. 1992;1:81-108. doi: 10.1007/978-94-011-2392-1_5. Dev Health Econ Public Policy. 1992. PMID: 10151755 Review. No abstract available.

57

[Value of utility measures: recurrent respiratory infections].

Launois R, Orvain J, Ounis I. Launois R, et al. Rev Epidemiol Sante Publique. 1992;40(1):46-55. Rev Epidemiol Sante Publique. 1992. PMID: 1604027 French.

58

Comparative health systems. France.

Rosa JJ, Launois R. Rosa JJ, et al. Among authors: launois r. Adv Health Econ Health Serv Res Suppl. 1990;1:179-95. Adv Health Econ Health Serv Res Suppl. 1990. PMID: 10113790 No abstract available.

59

[Economic lessons of large-scale thrombolytic trials].

Beaufils P, Blum-Boisgard C, Geffroy L, Hazebroucq G, Launois B, Launois R, Leclercq B, Viens-Bitker C. Beaufils P, et al. Among authors: launois r. Arch Mal Coeur Vaiss. 1989 Oct;82 Spec No 3:63-8. Arch Mal Coeur Vaiss. 1989. PMID: 2512890 French. No abstract available.

60

[Cost efficacy analysis of thrombolytic strategies].

Launois R, Launois B. Launois R, et al. Arch Mal Coeur Vaiss. 1989 Oct;82 Spec No 3:55-62. Arch Mal Coeur Vaiss. 1989. PMID: 2512889 French.

61

[Economic evaluation of therapeutic strategies. Finality, methods].

Launois R. Launois R. Arch Mal Coeur Vaiss. 1989 Oct;82 Spec No 3:43-7. Arch Mal Coeur Vaiss. 1989. PMID: 2512887 French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

61 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Results by year